Skip to content

US · SPRB · BIOTECHNOLOGY

Spruce Biosciences, Inc. (SPRB) intrinsic value and stock valuation

$38.00as of 2026-11-21 · Mkt cap 63.95M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Spruce Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values SPRB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPRB’s statements →

Spruce Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 sprucebio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-38.97M
20182025
Free cash flow
-$-33.33M
20182025
Total equity
$42.5M-22.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$4.91M$10.1M$0.00$0.00
Operating income-$-36.51M-$-56.15M-$-51.99M-$-47.28M-$-42.07M
Net income-$-38.97M-$-53.04M-$-47.92M-$-46.18M-$-42.29M
EPSd-$-50.61M-$-98.22M-$-95.84M-$-75.7M-$-69.33M
Operating cash flow-$-33.33M-$-55.96M-$-33.27M-$-41.68M-$-35.88M
Capital expenditure$0.00$0.00-$-10K-$-10K-$-90K
Free cash flow-$-33.33M-$-55.96M-$-33.28M-$-41.69M-$-35.97M
Total assets$53M$45.2M$104M$85.7M$126.5M
Total debt$740K$2.77M$4.61M$6.32M$6.53M
Net debt-$-48.17M-$-35.99M-$-91.73M-$-18.17M-$-36.22M
Total equity$42.5M$28.8M$76.5M$68.5M$111.4M
Cash and short-term investments$48.9M$38.8M$96.3M$79.1M$89M
Income statement
20252024202320222021
Revenue$0.00$4.91M$10.1M$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$4.91M$10.1M$0.00$0.00
Research and development expenses$19.5M$46.4M$49.4M$35.2M$30.7M
Selling, general and administrative expenses$17M$14.6M$12.7M$12.1M$11.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$36.5M$61.1M$62.1M$47.3M$42.1M
Cost and expenses$36.5M$61.1M$62.1M$47.3M$42.1M
Interest income$1.14M$3.42M$4.56M$1.52M$120K
Interest expense$90K$310K$480K$420K$340K
Depreciation and amortization$20K$50K$70K$70K$70K
Ebitda-$-38.85M-$-52.68M-$-47.37M-$-45.69M-$-41.88M
Operating income-$-36.51M-$-56.15M-$-51.99M-$-47.28M-$-42.07M
Total other income/expenses, net-$-2.45M$3.12M$4.07M$1.1M-$-230K
Income before tax-$-38.97M-$-53.04M-$-47.92M-$-46.18M-$-42.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-38.97M-$-53.04M-$-47.92M-$-46.18M-$-42.29M
Weighted average shares outstanding$770K$540K$500K$610K$610K
Weighted average diluted shares outstanding$770K$540K$500K$610K$610K
Balance sheet
20252024202320222021
Cash and short-term investments$48.9M$38.8M$96.3M$79.1M$89M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$52.1M$44.2M$102.2M$83.6M$91.9M
Property, plant and equipment, net$670K$930K$1.18M$1.4M$1.48M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00-$-54.54M$32.5M
Total non-current assets$910K$1M$1.76M$2.04M$34.6M
Total assets$53M$45.2M$104M$85.7M$126.5M
Accounts payable$940K$1.29M$3.33M$1.43M$2.82M
Short-term debt$320K$1.91M$1.87M$1.76M$360K
Deferred revenue$0.00$0.00$4.91M$0.00$0.00
Total current liabilities$10.1M$15.3M$24.5M$12.5M$8.87M
Long-term debt$420K$860K$2.74M$4.55M$6.17M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$420K$1.14M$2.97M$4.71M$6.24M
Capital lease obligations$740K$1.02M$1.27M$1.4M$1.65M
Total liabilities$10.5M$16.4M$27.4M$17.2M$15.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-289.23M-$-250.27M-$-197.23M-$-149.31M-$-103.13M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-560K-$-180K
Total equity$42.5M$28.8M$76.5M$68.5M$111.4M
Total investments$0.00$0.00$0.00$50K$78.7M
Total debt$740K$2.77M$4.61M$6.32M$6.53M
Net debt-$-48.17M-$-35.99M-$-91.73M-$-18.17M-$-36.22M
Cash flow statement
20252024202320222021
Net income-$-38.97M-$-53.04M-$-47.92M-$-46.18M-$-42.29M
Depreciation and amortization$20K$50K$70K$70K$70K
Stock-based compensation$2.57M$5.35M$4.62M$3.63M$3.96M
Change in working capital-$-720K-$-8.57M$10.4M$1.13M$1.96M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-350K-$-2.04M$1.91M-$-1.4M-$-810K
Net cash provided by operating activities-$-33.33M-$-55.96M-$-33.27M-$-41.68M-$-35.88M
Investments in property, plant and equipment$0.00$0.00-$-10K-$-10K-$-90K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$55.8M$23.7M-$-79.17M
Common stock issued$50M$250K$53.6M-$-200K$460K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$43.5M-$-1.62M$49.1M-$-240K$640K
Net change in cash$10.2M-$-57.59M$71.6M-$-18.05M-$-114.4M
Cash at end of period$48.9M$38.8M$96.4M$24.7M$43M
Operating cash flow-$-33.33M-$-55.96M-$-33.27M-$-41.68M-$-35.88M
Capital expenditure$0.00$0.00-$-10K-$-10K-$-90K
Free cash flow-$-33.33M-$-55.96M-$-33.28M-$-41.69M-$-35.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Spruce Biosciences, Inc.

        Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

        CEO
        Javier Szwarcberg
        Employees
        20
        Beta
        3.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Spruce Biosciences, Inc. (SPRB)?

        InvestorsCraft does not currently publish an intrinsic value for SPRB. How the IC value is calculated.

        Is SPRB undervalued?

        InvestorsCraft does not publish an undervaluation signal for SPRB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.